Furthermore, these metabolites may directly affect IECs after crossing the mucosal barrier, induce immunological responses in the intestinal stroma, release pro-inflammatory signals such as TNF and IL-17, or cause immunosuppression in the tumor microenvironment (TME). Here, IL17A is linked to neoplasm.